JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 3 filers reported holding JUNO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,000 | – | 73 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $83,627,000 | 94.97% |
| Crestline Management, LP | 9,348,799 | $419,387,000 | 58.30% |
| Omega Fund Management, LLC | 1,074,612 | $48,207,000 | 27.27% |
| PECONIC PARTNERS LLC | 570,000 | $25,570,000 | 4.12% |
| SIB LLC | 100,000 | $4,486,000 | 3.22% |
| Cormorant Asset Management, LP | 375,000 | $16,823,000 | 2.97% |
| BB BIOTECH AG | 2,055,000 | $92,187,000 | 2.55% |
| Clarius Group, LLC | 117,896 | $5,289,000 | 2.23% |
| Monashee Investment Management LLC | 122,000 | $5,473,000 | 2.07% |
| Iguana Healthcare Management, LLC | 150,000 | $6,730,000 | 1.86% |